Overview
- The impact of viral sequence diversity on this class of inhibitors is discussed
- Connection between basic research and clinical studies is shown
- Focuses on real-world issues, such as virus phenotyping in the clinic
- Unique collection of contributors from basic research, pharmaceutical research, and the clinic
- Includes supplementary material: sn.pub/extras
Part of the book series: Milestones in Drug Therapy (MDT)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (12 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
Entry Inhibitors in HIV Therapy details the current status of this relatively new and very dynamic class of inhibitors, appealing to both the clinician and basic research scientist. A unique overview of obstacles and accomplishments is presented. The book features chapters that explain the challenges of high sequence diversity in the viral envelope gene for the development and use of entry inhibitors, the clinical utility of virus phenotyping, the development of this class of inhibitors as microbicidal therapy, and the success story of enfuvirtide from the bench to FDA approval. Both basic research findings and results of clinical studies are covered and linked together by a diverse panel of experts in the field.
Editors and Affiliations
Bibliographic Information
Book Title: Entry Inhibitors in HIV Therapy
Editors: Jacqueline D. Reeves, Cynthia A. Derdeyn
Series Title: Milestones in Drug Therapy
DOI: https://doi.org/10.1007/978-3-7643-7783-0
Publisher: Birkhäuser Basel
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Birkhäuser Basel 2007
Hardcover ISBN: 978-3-7643-7782-3Published: 22 June 2007
eBook ISBN: 978-3-7643-7783-0Published: 08 August 2007
Series ISSN: 2296-6056
Series E-ISSN: 2296-6064
Edition Number: 1
Number of Pages: X, 206
Topics: Pharmacology/Toxicology, Immunology, Virology, Infectious Diseases, Pathology, Cell Biology